By reprogramming a 7–year–old girl’s own immune cells to attack an aggressive form of childhood leukemia, a pediatric oncologist has achieved a complete response in his patient, who faced grim prospects when she relapsed after conventional treatment. The innovative experimental therapy used bioengineered T cells, custom–designed to multiply rapidly in the patient, and then destroy leukemia cells. After the treatment, the child’s doctors found that she had no evidence of cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/50777-chop-engineered-immune-t-cell-therapy-anticancer-effect-in-children
Researchers have discovered that a subtype of leukemia characterized by a poor prognosis is fueled by mutations in pathways distinctly different from a seemingly similar leukemia associated with a much better outcome. The findings from the St. Jude Children’s Research Hospital — Washington University Pediatric Cancer Genome Project (PCGP) highlight a possible new strategy for treating patients with this more aggressive cancer.
The work provides the first details of the genetic alterations fueling a subtype of acute lymphoblastic leukemia (ALL) known as early T-cell precursor ALL (ETP-ALL). The results suggest ETP-ALL has more in common with acute myeloid leukemia (AML) than with other subtypes of ALL. The study appears in the January 12 edition of the journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46768-st-jude-cancer-genome-sequencing-project-combat-aggressive-leukemia
PokerStars.com announces another record-breaking event, the World's
Largest� Poker game played by members of the England Rugby Team.
PokerStars, the Official Gaming and Casino Partner of the England Rugby
team, has already broken records for the World\\\'s Largest Online Poker
Tournament� and Most Players on an Internet Poker Room�, and decided to
take on a real-world challenge, with some of the most aggressive and
competitive players the poker world has ever seen; England rugby stars James
Haskell (Stade Francais), Ben Foden (Northampton Saints) and Delon Armitage.
(London Irish). http://pokerstars.com
According to a national online survey released today by the Ad Council, only a third of parents in the United States are very concerned that lead poses a health risk to their children. However, lead poisoning affects more than one million children in the United States. If not detected early, children with high levels of lead in their bodies can suffer from damage to the brain and nervous system, behavior and learning problems (such as hyperactivity), slowed growth, hearing problems and aggressive behavior.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/adcouncil/43516/
New findings from the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project (PCGP) have helped identify the mechanism that makes the childhood eye tumor retinoblastoma so aggressive. The discovery explains why the tumor develops so rapidly while other cancers can take years or even decades to form.
The finding also led investigators to a new treatment target and possible therapy for the rare childhood tumor of the retina, the light-sensing tissue at the back of the eye. The study appears in the January 11 advance online edition of the scientific journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46767-st-jude-genome-project-treatment-childhood-eye-tumor-retinoblastoma
Imagine a device worn on your finger that allows intuitive, touch-free interaction with the digital world. Imagine a solar panel the size of a microcontroller that enables environmental intelligence in any building. Imagine integrating carbon monoxide sensing, thermostat control and biometric security capabilities to a smoke detector without increasing its size. This smarter, greener, battery-free world is fast becoming a reality with the world’s lowest-power microcontroller platform from Texas Instruments Incorporated (TI) (NASDAQ: TXN). Codenamed “Wolverine” for its aggressive power-saving technology, this ultra-low-power MSP430 microcontroller platform offers at least 50 percent less power consumption than any other microcontroller in the industry (360 nA real-time clock mode and less than 100 µA/MHz active power consumption). The first devices based on this platform will be the MSP430FR58xx microcontroller series with expected availability in June 2012.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54041-texas-instruments-ti-wolverine-microcontroller-platform
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
Nearly 90 percent of children and adults with a highly aggressive form of acute lymphoblastic leukemia (ALL) showed no evidence of cancer after receiving a novel, personalized cell therapy that reprograms a patient’s immune system. In pilot studies of bioengineered T cells that attack leukemia, 24 of 27 patients (89%) experienced complete responses within 28 days after treatment. In all, 27 patients received the treatment--22 children treated at The Children’s Hospital of Philadelphia and five adults treated at the Hospital of the University of Pennsylvania.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64394-chop-penn-harness-engineered-t-cells-eliminate-tumors-in-blood-leukemia
Hearkening back to the glory days of purebred, affordable sports cars, Kia Motors America (KMA) today unveiled the brand’s most aggressive concept car ever when wraps came off the GT4 Stinger at the North American International Auto Show (NAIAS). Kia’s eye-catching design language moves in a bold new direction with the introduction of the GT4 Stinger. The concept pushes the boundaries of performance with a rear-drive 2+2 sports car that places man and machine in harmony on the road or track. It comes as no surprise that the GT4 Stinger is the wild style child of Kia’s California design team, home to its 2012 predecessor, the Track’ster concept. And like the Track’ster, the GT4 Stinger’s racy appeal is more than skin deep.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65141-kia-shocks-the-motor-city-rear-drive-gt4-stinger-2014-naias
The National Mining Association (NMA) called on policymakers to reject an ill-conceived administration proposal that would jeopardize America’s electric grid and threaten the economic well-being of consumers and businesses. Recently, the Environmental Protection Agency’s (EPA) proposed aggressive guidelines for regulating greenhouse gas emissions from existing coal-based power plants that generate 40 percent of the nation’s electricity and which will raise the cost of electricity for all Americans, according to NMA.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7221751-national-mining-association-affordable-reliable-electricity/
In partnership with Men’s Health Network (MHN), Prostate Health Education Network (PHEN), ZERO – the End of Prostate Cancer and Joe Torre, four-time world champion baseball Hall-of-Famer and prostate cancer survivor, Genomic Health, Inc. (Nasdaq: GHDX) today launched Your Prostate Your Decision to educate prostate cancer patients and their loved ones that every man is different and every cancer is unique, and a genomic test can clarify the aggressiveness of one’s disease prior to invasive treatment. This first-of-its-kind national effort aims to address concerning results of a large national survey that found low general awareness about prostate cancer aggressiveness and treatment options, underscoring the need for better understanding of active surveillance as a treatment plan.
“For a man with prostate cancer, a single decision can change his entire life,” said Mr. Torre, reflecting on his own experience with prostate cancer. “When I was diagnosed with prostate cancer, I faced a game-changing decision. While I chose surgery, a less aggressive approach called active surveillance might be the best choice.”
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7322251-your-prostate-your-decision-joe-torre-talks-about-prostate-cancer-genomic-testing-treatment-options-psa/
The Leukemia & Lymphoma Society (LLS) today announced it has committed $28.6 million in new research investment to advance the most promising blood cancer science at leading academic and medical institutions around the world, including Dana-Farber Cancer Institute, Weill Cornell Medical College and MD Anderson Cancer Center. As LLS leads the charge to find cures for cancer patients, this new funding, along with ongoing investment in LLS’s aggressive research agenda, brings LLS’s total commitment to blood cancer research to more than $1 billion. The investment has led to the development of nearly every therapy currently used to treat the blood cancers.
Along with these new research grants, LLS remains committed to collaborating with biotechnology companies through its innovative Therapy Acceleration Program® (TAP), a model pioneered by LLS in the cancer arena in recognition that traditional research approaches weren’t yielding treatments and cures fast enough for patients. LLS commits approximately $13 million a year to its TAP initiatives. As part of the 24 current such collaborations, LLS recently initiated new investments with Kite Pharma and OncoPep.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554852-lls-cancer-research-funding/
